Clinical Research

临床研究办公室共享资源（CRO）监督诺里斯棉花癌症中心临床试验的审查、启动、实施和安全监测。CRO组成人员包括1)行政人员，包括共享资源主任、副主任、助理主任、财务经理和礼宾助理；2)特定方案研究支持人员，包括一名研究药剂师、一名药学技术人员、两名研究注册护士和16名临床研究助理/协调员；3)方案审查和监测系统，由临床癌症研究委员会（CCRC）和安全与数据监测委员会（SDMC）组成；4)达特茅斯-希区柯克肿瘤登记处，由三名登记员组成。虽然DHMC和NCCC已经指定CRO负责临床癌症研究的所有方面的行政监督，包括医院肿瘤登记，但我们对CCSG资金的要求是更狭隘的

The Clinical Research Office Shared Resource (CRO) oversees the review, initiation, conduct, and safety monitoring of clinical trials at the Norris Cotton Cancer Center. The CRO components are 1) an administrative staff including the Shared Resource Director, an Associate Director, an Assistant Director, a financial manager, and a protocol assistant; 2) the Protocol-Specific Research Support staff, comprising a research pharmacist, a pharmacy technician, two research registered nurses, and 16 clinical research assistants / coordinators; 3) the Protocol Review and Monitoring System, consisting of the Clinical Cancer Research Committee (CCRC) and the Safety and Data Monitoring Committee (SDMC); and 4) the Dartmouth-Hitchcock Tumor Registry, staffed by three registrars. Although DHMC and the NCCC have designated the CRO as the office responsible for administrative oversight of all aspects of clinical cancer research including the hospital tumor registry, our request for CCSG funding is for the more narrowly defined functions of this Shared Resource related to support peer-reviewed clinical trials of cancer treatment and chemoprevention. The CRO maintains local Dartmouth Medical School studies, working group studies, cooperative group protocols, and industrial trials. It is responsible for assisting in formatting protocols, writing consent forms, maintaining Institutional Review Board and SDMC records, developing budgets, assessing impact on institutional resources, activating protocols, assessing eligibility, developing data collection forms and databases, and collecting and managing data. Prioritization of clinical trials is determined within the 12 NCCC Clinical Oncology Groups, with approval by the CCRC. The CRO acts as a checkpoint prior to activation of protocols to ensure that all appropriate administrative aspects of trials are complete. Charge-back policies of the CRO accurately reflect usage, and are based on patient accrual to reviewed and approved protocols.